Gastroenterology Research and Practice / 2013 / Article / Tab 2

Research Article

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo

Table 2

Comparing HCC growth treated by NET-1shRNA alone and in combination with sorafenib.

GroupsMHCC97H (cm3)

NET-1shRNA1.354 ± 0.042●★
Sorafenib 1.201 ± 0.152●★
Combination0.558 ± 0.018
Untreated3.459 ± 0.121
Empty vector3.279 ± 0.084

The average tumor size in each group was 1.354 ± 0.042 cm3, 1.201 ± 0.152 cm3, 0.558 ± 0.018 cm3, and 3.459 ± 0.121 cm3, respectively, ( compared with untreated group. compared with combination group).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.